Inhibikase Therapeutics, Inc. (IKT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.50-0.79%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IKT
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | — | — | — | 0.3 | 0.1 | 3.1 | 0.7 |
| Operating Expenses & Income | |||||||
| Selling, General & Admin | 27.4 | 23.6 | 11.4 | 6.7 | 6.2 | 6.5 | 2.6 |
| R&D Expenses | 38.2 | 29.8 | 17.2 | 13.6 | 12.0 | 11.4 | 0.9 |
| Operating Income | (65.4) | (52.0) | (28.6) | (20.1) | (18.1) | (14.8) | (2.8) |
| Earnings from Continuing Operations | |||||||
| Interest Expense | — | — | — | — | — | 0.0 | 0.0 |
| EBT, Incl. Unusual Items | — | (0.0) | — | — | — | — | — |
| Net Income | |||||||
| Net Income | (60.6) | (48.3) | (27.5) | (19.0) | (18.1) | (14.8) | (2.8) |
| Per Share | |||||||
| Basic EPS | (0.35) | (0.49) | (1.16) | (3.16) | (4.28) | (0.81) | — |
| Diluted EPS | (0.35) | (0.49) | (1.16) | (3.16) | (4.28) | (0.81) | — |
| Basic Weighted Avg Shares | 174.6 | 98.3 | 23.7 | 6.0 | 4.2 | 18.2 | — |
| Diluted Weighted Avg Shares | 174.6 | 98.3 | 23.7 | 6.0 | 4.2 | 18.2 | — |
| Supplemental | |||||||
| EBIT | (65.4) | (52.0) | (28.6) | (20.1) | (18.1) | (14.8) | (2.8) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.